

Literární zdroje

Kapitola 1: Epidemiologie karcinomu prsu

- Bielčíková Z. Karcinom prsu u mužů. *Onkologie*. 2016; 10(4): 170–174.
- Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. *Epidemiologie zhoubných nádorů v České republice* [Internet]. Brno: Masarykova univerzita; 2005 [cit. 2020-11-03]. Dostupné z: <http://www.svod.cz>.
- Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. *Global Cancer Observatory: Cancer Today* [Internet]. Lyon, France: International Agency for Research on Cancer; 2018 [cit. 2018-10-04]. Dostupné z: <https://gco.iarc.fr/today>.
- Mamo.cz – Program mamografického screeningu v České republice [Internet]. Brno: Masarykova univerzita; 2019 [cit. 2020-11-03]. Dostupné z: <http://www.mamo.cz>.
- Mužík J, Dušek L, Abrahámová J, Koptíková J. Stručný přehled epidemiologie zhoubného novotvaru prsu v České republice. *Onkologie*. 2009; 3(1): 7–11.
- Ústav zdravotnických informací a statistiky ČR: *Národní onkologický registr (NOR)*. Praha: ÚZIS; 2020 [cit. 2020-11-03]. Dostupné z: <http://www.uzis.cz/registry-nzis/nor>.

Kapitola 2: Screening karcinomu prsu pro praxi

- Alberdi RZ, Llanes AB, Ortega RA, et al. Effect of radiologist experience on the risk of false-positive results in breast cancer screening programs. *Eur Radiol*. 2011; 21: 2083–2090.
- Blanch J, Sala M, Ibáñez J, Domingo L, Fernandez B, Otegi A, et al. Impact of risk factors on different interval cancer subtypes in a population-based breast cancer screening programme. *PLoS One*. 2014; 9(10): e110207.
- Brodersen J, Schwartz LM, Heneghan C, et al. Overdiagnosis: what it is and what it isn't. *BMJ Evidence-based Medicine*. 2018; 23: 1–3.
- Canelo-Aybar C, Ferreira DS, Ballesteros M, et al. Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. *J Med Screen*. 2021 Feb 25: 969141321993866.
- Česká onkologická společnost ČLS JEP. *Modrá kniha České onkologické společnosti*. 27. aktualizace [Internet]. Brno: Masarykův onkologický ústav; 2021 [cit. 2021-03-01]. Dostupné z: <https://www.linkos.cz/lekar-a-multidisciplinari-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/>.
- Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A, et al. Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers. *Eur J Cancer Prev*. 2013 Jan; 22(1): 21–28.
- Duijm LEM, et al. Inter-observer variability in mammography screening and effect of type and number of readers on screening outcome. *Br J Cancer*. 2009; 100(6): 901–907.
- Epidemiologie: výukové texty pro studenty 1*. LF UK. Praha: Karolinum; 2002. 168 s.
- European Commission Initiative on Breast Cancer (ECIBC). *Breast cancer guidelines and quality assurance* [Internet]. Ispra: JRC; 2021 [cit. 2021-03-12]. Dostupné z: <https://healthcare-quality.jrc.ec.europa.eu/>.

- Greenhalgh T. *Jak pracovat s vědeckou publikací: základy medicíny založené na důkazu*. 1. vyd. Praha: Grada Publishing; 2003. 208 s.
- Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. *Cancer*. 2011; 117(4): 714–722.
- Hoff SR, Myklebust TÅ, Lee CI, Hofvind S. Influence of Mammography Volume on Radiologists' Performance: Results from BreastScreen Norway. *Radiology*. 2019; 292(2): 289–296.
- Houssami N, Hunter K. The epidemiology, radiology, and biological characteristics of interval breast cancers in population mammography screening. *NPJ Breast Cancer*. 2017 Apr 13; 3: 12.
- Lowery JT, Byers T, Hokanson JE, et al. Complementary approaches to assessing risk factors for interval breast cancer. *Cancer Causes & Control*. 2011; 22: 23–31.
- Májek O, et al. *Mezinárodní data o screeningu karcinomu prsu* [Internet]. Brno: Datový audit mamografického screeningu 2018; 2018 [cit. 2021-03-15]. Dostupné z: <https://www.mamo.cz/res/file/datovy-audit-prezentace/2018/06-majek.pdf>.
- Mamo.cz – *Program mamografického screeningu v České republice. Doporučení KOMD k vykazování výkonů a diagnóz ve screeningovém a diagnostickém vyšetřování prsů* (s platností od 1. 11. 2019) [Internet]. Brno: Masarykova univerzita; 2019 [cit. 2021-03-01]. Dostupné z: <https://www.mamo.cz/cs/lekari/indikace/vykazovani-vykonu-a-diagnoz/>.
- Mamo.cz – *Program mamografického screeningu v České republice. Mapa screeningových center* [Internet]. Brno: Masarykova univerzita; 2019 [cit. 2021-03-01]. Dostupné z: <https://www.mamo.cz/centra/>.
- Ministerstvo zdravotnictví ČR. *Věstník MZ ČR č. 3 /2021* [Internet]. Praha: Ministerstvo zdravotnictví ČR; 2021 [cit. 2021-03-01]. Dostupné z: https://www.mzcr.cz/wp-content/uploads/2021/03/Vestnik-MZ_3-2021.pdf.
- Ministerstvo zdravotnictví ČR. *Věstník MZ ČR č. 4/2010* [Internet]. Praha: Ministerstvo zdravotnictví ČR; 2010 [cit. 2021-03-01]. Dostupné z: <https://www.mamo.cz/res/file/legislativa/vestnik-mzcr-04-2010.pdf>.
- Rebolj M, Assi V, Brentnall A, et al. Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis. *Br J Cancer*. 2018; 118(12): 1559–1570.
- VZP ČR. *Metodika pro pořizování a předávání dokladů*. Verze popisu 6. 2. XXXVIII [Internet]. Praha: Ústředí VZP ČR; 2020 [cit. 2021-03-01]. Dostupné z: <https://media.vzpstatic.cz/media/Default/dokumenty/vyuctovani/metodika-pro-porizovani-a-predavani-dokladu-k-1.-8.-2020.pdf>.
- Weber RJP, van Bommel RMG, Louwman MW, Nederend J, Voogd AC, Jansen FH, et al. Characteristics and prognosis of interval cancers after biennial screen-film or full-field digital screening mammography. *Breast Cancer Res Treat*. 2016 Aug; 158(3): 471–483.
- Welch HG, Black WC. Overdiagnosis in cancer. *J Natl Cancer Inst*. 2010; 102(9): 605–613.
- Welch HG, Schwartz LM, Woloshin S. Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers. *BMJ*. 2006; 332(7543): 727.

Zackrisson S, Andersson I, Janzon L, et al. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. *BMJ*. 2006; 332(7543): 689–692.

Kapitola 3: Informační podpora a výsledky Národního programu screeningu karcinomu prsu v České republice

Mamo.cz – Program mamografického screeningu v České republice [Internet]. Brno: Masarykova univerzita; 2019 [cit. 2020-11-03]. Dostupné z: <http://www.mamo.cz>.

OECD/EU. *Health at a Glance: Europe 2018: State of Health in the EU Cycle* [Internet]. Paris: OECD Publishing; 2019 [cit. 2020-11-03]. Dostupné z: https://doi.org/10.1787/health_glance_eur-2018-en.

Ponti A, Anttila A, Ronco G, Senore C, Basu P, Segnan N, et al. *Cancer screening in the European Union (2017). Report on the implementation of the Council Recommendation on cancer screening (second report)* [Internet]. Brussels: European Commission; 2017 [cit. 2020-11-03]. Dostupné z: <https://screening.iarc.fr/EUreport.php>.

Kapitola 4: Histopatologická diagnostika karcinomu prsu

Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update. *J Clin Oncol*. 2020; 38(12): 1346–1366.

WHO Classification of Tumours Editorial Board. *Breast Tumours: WHO Classification of Tumours*. 5th ed. Lyon: WHO; 2019. 368 p.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *J Clin Oncol*. 2018 Jul 10; 36(20): 2105–2122.

Kapitola 5: Karcinom prsu a dědičnost

Büchler T, et al. *Obecná onkologie*. Praha: Maxdorf; 2019. 384 s.

Foretová L, Macháčková E, Palácová M, et al. Doporučení rozšíření indikačních kritérií ke genetickému testování mutací v genech *BRCA1* a *BRCA2* u hereditárního syndromu nádorů prsu a ovarií. *Klin Onkol*. 2016; 29(Suppl 1): 9–13.

Foretová L, Navrátilová M, Svoboda M, et al. Doporučení pro sledování žen se vzácnějšími genetickými příčinami nádorů prsu a ovarií. *Klin Onkol*. 2019; 32(Suppl 2): 6–13.

National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic [Internet]. Plymouth Meeting, PA: NCCN; 2021 [cit. 2021-02-28]. Dostupné z: <https://www.nccn.org/>.

Kapitola 6: Rizikové faktory vzniku karcinomu prsu

Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. *J Natl Cancer Inst*. 2010; 102(10): 680–691.

Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. *Breast*. 2004; 13(2): 85–92.

Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in *BRCA* mutation carriers: a meta-analysis. *Expert Rev Anticancer Ther*. 2011 Aug; 11(8): 1197–1207.

- Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer: collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease. *Br J Cancer*. 2002; 87(11): 1234–1245.
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. *Lancet*. 1997; 350(9084): 1047–1059.
- Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. *Lancet*. 2001; 358(9291): 1389–1399.
- Derks-Smeets IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, et al. Ovarian stimulation for IVF and risk of primary breast cancer in *BRCA1/2* mutation carriers. *Br J Cancer*. 2018 May 1; 119(3): 357–363.
- Chen WY. *Menopausal hormone therapy and the risk of breast cancer* [Internet]. Waltham, MA: UpToDate Inc.; 2020 [cit. 2021-03-01]. Dostupné z: <https://www.uptodate.com/contents/menopausal-hormone-therapy-and-the-risk-of-breast-cancer>.
- Kroener L, Dumesic D, Al-Safi Z. Use of fertility medications and cancer risk: a review and update. *Curr Opin Obstet Gynecol*. 2017 Aug; 29(4): 195–201.
- Mamo.cz – Program mamografického screeningu v České republice. Clausův model k odhadu celoživotního kumulativního rizika vzniku nádorů prsu u žen s pozitivní rodinnou anamnézou [Internet]. Brno: Masarykova univerzita; 2019 [cit. 2021-03-01]. Dostupné z: <https://www.mamo.cz/cs/lekari/indikace/clausuv-model/>.
- Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet*. 2003; 362(9382): 419–427.
- Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. *N Engl J Med*. 2017; 377(23): 2228–2239.
- van den Belt-Dusebout AW, Spaan M, Lambalk CB, et al. Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer. *JAMA*. 2016; 316(3): 300–312.
- Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. *JAMA*. 2002; 288(3): 321–333.
- Zikán M. Gynekologická prevence a gynekologické aspekty péče u nosiček mutací genů *BRCA1* a *BRCA2*. *Klin Onkol*. 2016; 29(Suppl 1): S22–30.
- Kapitola 7: Samovyšetření, klinické vyšetření prsu**
- Anderson BO, Bevers TB, Carlson RW. Clinical Breast Examination and Breast Cancer Screening Guideline. *JAMA*. 2016; 315(13): 1403–1404.
- Cady B, Steele GD Jr, Morrow M, Gardner B, et al. Evaluation of common breast problems: guidance for primary care providers. *CA Cancer J Clin*. 1998 Jan-Feb; 48(1): 49–63.
- Black WC. Overdiagnosis in cancer. *J Natl Cancer Inst*. 2004; 96(10): 1002–1009.
- Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. *Cochrane Database of Systematic Reviews*. 2003; 2: CD003373.
- Santen RJ, Mansel R. Benign breast disorders. *N Engl J Med*. 2005; 353(3): 275–285.

Kapitola 8: Základní klinické příznaky karcinomu prsu, diferenciální diagnostika

- Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). *Breast Dis.* 2005; 22: 9–23.
- Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. *Ann Oncol.* 2011; 22(3): 515–523.
- Dixon JM, Pariser KM. *Nonlactational mastitis in adults* [Internet]. Waltham, MA: UpToDate Inc.; 2021 [cit. 2021-03-01]. Dostupné z: <https://www.uptodate.com/contents/nonlactational-mastitis-in-adults>.
- Dixon JM. *Lactational mastitis* [Internet]. Waltham, MA: UpToDate Inc.; 2020 [cit. 2021-03-01]. Dostupné z: <https://www.uptodate.com/contents/lactational-mastitis>.
- Goyal A. Breast pain. *BMJ Clin Evid.* 2011 Jan 17; 2011: 0812.
- Matro JM, Li T, Cristofanilli M, et al. Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. *Clin Breast Cancer.* 2015; 15(1): 1–7.
- Minář L, Al Awad H, Kümmel J. Paraneoplastické syndromy v onkogynekologii. *Čes Gynek.* 2009; 74(3): 171–176.
- Pirti O, Barlas AM, Kuru S, et al. Mastalgia due to degenerative changes of the spine. *Adv Clin Exp Med.* 2016; 25(5): 895–900.
- Prošková M. *Možnosti rehabilitace při léčbě mastodynii*. Kladno, 2015. Bakalářská práce. ČVUT, Fakulta biomedicínského inženýrství.
- Scurr J, Hedger W, Morris P, Brown N. The prevalence, severity, and impact of breast pain in the general population. *Breast J.* 2014 Sep-Oct; 20(5): 508–513.
- Strnad P, Daneš J. *Nemoci prsu pro gynekology*. Praha: Grada Publishing; 2001. 324 s.

Kapitola 9: Vývoj prsu a hormonů

- Chen WY. *Menopausal hormone therapy and the risk of breast cancer* [Internet]. Waltham, MA: UpToDate Inc.; 2020 [cit. 2021-03-01]. Dostupné z: <https://www.uptodate.com/contents/menopausal-hormone-therapy-and-the-risk-of-breast-cancer>.

Kapitola 10: Benigní změny a změny s vyšším rizikem karcinomu prsu

- Myers DJ, Walls AL. Atypical Breast Hyperplasia. In: *StatPearls* [Internet]. Treasure Island, FL: StatPearls Publishing; 2020 [cit. 2020-07-21]. Dostupné z: <https://www.ncbi.nlm.nih.gov/books/NBK470258/>.
- Pavlišta D. Bolesti prsu, rezistence v prsu a sekrece z prsu a jejich diferenciální diagnostika. *Moderní gynekologie a porodnictví.* 2008; 17(4).
- Roe A, Bartz DA, Douglas PS. *Combined estrogen-progestin contraception: Side effects and health concerns* [Internet]. Waltham, MA: UpToDate Inc.; 2021 [cit. 2021-03-01]. Dostupné z: <https://www.uptodate.com/contents/combined-estrogen-progestin-contraception-side-effects-and-health-concerns>.
- Russo J. *Breast development and morphology* [Internet]. Waltham, MA: UpToDate Inc.; 2021 [cit. 2021-03-01]. Dostupné z: <https://www.uptodate.com/contents/breast-development-and-morphology>.
- Schnitt SJ. Benign breast disease and breast cancer risk: morphology and beyond. *Am J Surg Pathol.* 2003; 27(6): 836–841.
- Strnad P, Daneš J. *Nemoci prsu pro gynekology*. Praha: Grada Publishing; 2001. 324 s.

The American Society of Breast Surgeons. *Consensus guideline on concordance assessment of image-guided breast biopsies and management of borderline or high-risk lesions. Official statement* [Internet]. Columbia, MD: The American Society of Breast Surgeons; 2016 [cit. 2021-03-01]. Dostupné z: <https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf>.

Kapitola 11: Zobrazovací metody

Alvarez S, Añorbe E, Alcorta P, et al. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. *AJR Am J Roentgenol*. 2006; 186(5): 1342–1348.

American Cancer Society. *American Cancer Society Recommendations for the Early Detection of Breast Cancer* [Internet]. Oklahoma City, OK: ACS; 2020 [cit. 2021-03-01]. Dostupné z: <https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html>.

American College of Radiology. *ACR BI-RADS® Atlas. 5th Edition* [Internet]. Reston, VA: ACR; 2013 [cit. 2021-03-01]. Dostupné z: <https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Bi-Rads>.

Barr RG. *Breast Elastography*. New York: Thieme Publishers; 2015. 165 p.

Bathla L, Harris A, Davey M, Sharma P, Silva E. High resolution intra-operative two-dimensional specimen mammography and its impact on second operation for re-excision of positive margins at final pathology after breast conservation surgery. *Am J Surg*. 2011; 202(4): 387–94.

Bedi DG, Krishnamurthy R, Krishnamurthy S, et al. Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study. *AJR Am J Roentgenol*. 2008; 191(3): 646–652.

Berná-Serna JD, Torres-Ales C, Berná-Mestre JD, Polo L. Role of Galactography in the Early Diagnosis of Breast Cancer. *Breast Care (Basel)*. 2013; 8(2): 122–126.

European Commission Initiative on Breast Cancer (ECIBC). *Breast cancer guidelines and quality assurance* [Internet]. Ispra: JRC; 2021 [cit. 2021-03-12]. Dostupné z: <https://healthcare-quality.jrc.ec.europa.eu/>.

Fallenberg EM, Dromain C, Diekmann F, et al. Contrast-enhanced spectral mammography versus MRI: initial results in the detection of breast cancer and assessment of tumour size. *Eur Radiol*. 2014; 24(1): 256–264.

Friedewald SM, Rafferty EA, Rose SL, et al. Breast Cancer Screening Using Tomosynthesis in Combination with Digital Mammography. *JAMA*. 2014; 311(24): 2499–2507.

Gaddey HL, Riegel AM. Unexplained Lymphadenopathy: Evaluation and Differential Diagnosis. *Am Fam Physician*. 2016 Dec 1; 94(11): 896–903.

Gennaro G, Bernardi D, Houssami N. Radiation dose with digital breast tomosynthesis compared to digital mammography: per-view analysis. *Eur Radiol*. 2018; 28(2): 573–581.

Gilbert FJ, Tucker L, Young KC. Digital breast tomosynthesis (DBT): a review of the evidence for use as a screening tool. *Clin Radiol*. 2016 Feb; 71(2): 141–150.

Houssami N, Ciatto S, Turner RM, et al. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: Meta-analysis of its accuracy and utility in staging the axilla. *Ann Surg*. 2011; 254(2): 243–251.

- Houssami N, Kirkpatrick-Jones G, Noguchi N, Lee CI. Artificial Intelligence (AI) for the early detection of breast cancer: a scoping review to assess AI's potential in breast screening practice. *Expert Rev Med Devices*. 2019; 16(5): 351–362.
- James JJ, Tennant SL. Contrast-enhanced spectral mammography (CESM). *Clin Radiol*. 2018 Aug; 73(8): 715–723.
- Jochelson MS, Dershaw DD, Sung JS, et al. Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. *Radiology*. 2013; 266(3): 743–751.
- Mechl M, Žižka J, Tintěra J, et al. Kontraindikace a rizika vyšetření pomocí magnetické rezonance. *Čes Radiol*. 2010; 64(1): 69–75.
- Melsaether A, Moy L. Breast PET/MR Imaging. *Radiol Clin North Am*. 2017 May; 55(3): 579–589.
- Patel BK, Lobbes MBI, Lewin J. Contrast enhanced spectral mammography: a review. *Semin Ultrasound CT MR*. 2018; 39(1): 70–79.
- Rose SL, Tidwell AL, Bujnoch LJ, et al. Implementation of Breast Tomosynthesis in a Routine Screening Practice: An Observational Study. *AJR Am J Roentgenol*. 2013; 200(6): 1401–1408.
- Sickles EA, D'Orsi CJ, Bassett LW, et al. *ACR BI-RADS® Atlas, Breast imaging reporting and data system*. Reston, VA: American College of Radiology. 2013: 39–48.
- Skaane P, Bandos AI, Eben EB, et al. Two-View Digital Breast Tomosynthesis Screening with Synthetically Reconstructed Projection Images: Comparison with Digital Breast Tomosynthesis with Full-Field Digital Mammographic Images. *Radiology*. 2014; 271(3): 655–663.
- Slobodníková J. *Včasná diagnostika a skrining karcinomu prsníka*. Trenčín: Rádiologická klinika, s.r.o.; 2011. 235 s.
- Stavros AT. *Breast Ultrasound*. Philadelphia, PA: Lippincott Williams and Wilkins; 2004. 864 p.
- Súkupová L. *Radiační ochrana při rentgenových výkonech – to nejdůležitější pro praxi*. Praha: Grada Publishing; 2018. 280 s.
- Ulaner GA. PET/CT for patients with breast cancer: Where is the clinical impact? *AJR Am J Roentgenol*. 2019 Aug; 213(2): 254–265.
- Vinnicombe SJ. Breast density: why all the fuss? *Clin Radiol*. 2018 Apr; 73(4): 334–357.
- Vydra J, Daneš J, Bartoš M, et al. *Metodika ultrazvukového vyšetření prsou*. Příloha k průběžné zprávě projektu TAČR TA04011392. UTIA 2017. 40 s.

Kapitola 12: Intervence v prsní diagnostice

- Coufal O. Možnost eliminace axilárních disekcí u pacientek s karcinomem prsu pomocí neoadjuvantní léčby. *Rozhl Chir*. 2016; 95(11): 381–385.
- Douek M, Klaase J, Monypenny I, et al. Sentinel node biopsy using a magnetic tracer vs. standard technique: The SentiMAG Multicentre Trial. *Ann Surg Oncol*. 2014; 21(4): 1237–1245.
- Gatek J, Petru V, Kosac P, et al. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer. *Neoplasma*. 2020; 67(6): 1329–1334.
- Gatěk J, Vrána D, Dudešek B, Duben J. Můžeme se vyhnout disekci axilárních lymfatických uzlin? *Rozhl Chir*. 2017; 96(8): 318–323.

- Goudreau SH, Joseph JP, Seiler SJ. Preoperative Radioactive Seed Localization for Nonpalpable Breast Lesions: Technique, Pitfalls, and Solutions. *Radiographics*. 2015 Sep-Oct; 35(5): 1319–1334.
- Harvey JR, Lim Y, Murphy J, et al. Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study. *Breast Cancer Res Treat*. 2018; 169(3): 531–536.
- Cheang E, Ha R, Thornton CM, Mango VL. Innovations in image-guided preoperative breast lesion localization. *Br J Radiol*. 2018; 91(1085): 20170740.
- Chvalný P, Sabol M. *Chirurgická liečba včasného karcinomu prsníka*. In: Slobodníková J. *Včasná diagnostika a skrining karcinomu prsníka*. Trenčín: Rádiologická klinika, s.r.o.; 2011. s. 151–168.
- Janssen NNY, Nijkamp J, Alderliesten T, Loo CE, Rutgers EJT, Sonke JJ, Vrancken Peeters MTFD. Radioactive seed localization in breast cancer treatment. *Br J Surg*. 2016 Jan; 103(1): 70–80.
- Kapoor MM, Patel MM, Scoggins ME. The Wire and Beyond: Recent Advances in Breast Imaging Preoperative Needle Localization. *Radiographics*. 2019 Nov-Dec; 39(7): 1886–1906.
- Klein RL, Mook JA, Euhus DM, Rao R, Wynn RT, Eastman AB, Leitch AM. Evaluation of a hydrogel based breast biopsy marker (HydroMARK®) as an alternative to wire and radioactive seed localization for non-palpable breast lesions. *J Surg Oncol*. 2012 May; 105(6): 591–594.
- Rose A, Collins JP, Neerhut P, Bishop CV, Mann GB. Carbon localisation of impalpable breast lesions. *Breast*. 2003 Aug; 12(4): 264–269.
- Thomassin-Naggara I, Lalonde L, David J, Darai E, Uzan S, Trop I. A plea for the biopsy marker: how, why and why not clipping after breast biopsy? *Breast Cancer Res Treat*. 2012 Apr; 132(3): 881–893.

Kapitola 13: Tumorové markery u karcinomu prsu

- Česká onkologická společnost ČLS JEP. *Modrá kniha České onkologické společnosti*. 27. aktualizace [Internet]. Brno: Masarykův onkologický ústav; 2021 [cit. 2021-03-01]. Dostupné z: <https://www.linkos.cz/lekar-a-multidisciplinari-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/>.
- Česká společnost klinické biochemie ČLS JEP. *Doporučení k využití nádorových markerů v klinické praxi* [Internet]. Praha: ČSKB; 2008 [cit. 2021-03-01]. Dostupné z: <https://www.cskb.cz/doporučení/archiv-doporučení/>.
- Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. *Clin Cancer Res*. 2001 Aug; 7(8): 2357–2362.
- Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. *Eur J Cancer*. 2002 Jun; 38(9): 1189–1193.
- National Comprehensive Cancer Network [Internet]. Plymouth Meeting, PA: NCCN; 2021 [cit. 2021-03-01]. Dostupné z: <https://www.nccn.org/>.

Kapitola 14: Karcinom prsu u vybraných skupin

- Atlan M, Nuti G, Wang H, Decker S, et al. Breast implant surface texture impacts host tissue response. *J Mech Behav Biomed Mater*. 2018; 88: 377–385.

- Atlan M, Bigerelle M, Larreta-Garde V, Hindié M, Hedén P. Characterization of breast implant surfaces, shapes, and biomechanics: a comparison of high cohesive anatomically shaped textured silicone, breast implants from three different manufacturers. *Aesthetic Plast Surg.* 2016; 40(1): 89–97.
- Azim HA Jr, Peccatori FA, de Azambuja E, Piccart MJ. Motherhood after breast cancer: searching for la dolce vita. *Expert Rev Anticancer Ther.* 2011; 11(2): 287–298.
- Barr S, Hill EW, Bayat A. Functional biocompatibility testing of silicone breast implants and a novel classification system based on surface roughness. *J Mech Behav Biomed Mater.* 2017; 75: 75–81.
- Bielčíková Z. Karcinom prsu u mužů. *Onkologie.* 2016; 10(4): 170–174.
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast Cancer and Breast-feeding: Collaborative Reanalysis of Individual Data from 47 Epidemiological Studies in 30 Countries, Including 50 302 Women With Breast Cancer and 96 973 Women Without the Disease. *Obstet Gynecol Surv.* 2003; 58(2): 94–95.
- de Boer M, van Leeuwen FE, Hauptmann M, et al. Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. *JAMA Oncol.* 2018; 4(3): 335–341.
- de Bree E, Makrigiannakis A, Askoxylakis J, Melissas J, Tsiiftsis DD. Pregnancy after breast cancer. A comprehensive review. *J Surg Oncol.* 2010; 101(6): 534–542.
- Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. *Epidemiologie zhoubných nádorů v České republice* [Internet]. Brno: Masarykova univerzita; 2005 [cit. 2020-11-03]. Dostupné z: <http://www.svod.cz>.
- Fernandes AFC, Santos MCL, de Castro e Silva TB, Galvão CM. Prognosis of breast cancer during pregnancy: evidence for nursing care. *Rev Lat Am Enfermagem.* 2011; 19(6): 1453–1461.
- Food and Drug Administration. *FDA Updates Analysis of Medical Device Reports of Breast Implant Illness and Breast Implant-Associated Lymphoma* [Internet]. Silver Spring, MD: FDA; 2020 [cit. 2020-08-20]. Dostupné z: <https://www.fda.gov/news-events/press-announcements/fda-updates-analysis-medical-device-reports-breast-implant-illness-and-breast-implant-associated>.
- Gaddam S, Heller SL, Babb JS, Gao Y. Male Breast Cancer Risk Assessment and Screening Recommendations in High-Risk Men Who Undergo Genetic Counseling and Multigene Panel Testing. *Clin Breast Cancer.* 2021; 21(1): e74–e79.
- Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, et al. Systemic Stromal Effects of Estrogen Promote the Growth of Estrogen Receptor-Negative Cancers. *Cancer Res.* 2007; 67(5): 2062–2071.
- Harvell DME, Kim J, O'Brien J, Tan A-C, Borges VF, Schedin P, et al. Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone. *Horm Cancer.* 2013; 4(3): 140–153.
- Heresová J, Vrzáňová M. Gynekomastie. *Interní medicína pro praxi.* 2003; 1: 6–9.
- Inman JL, Robertson C, Mott JD, Bissell MJ. Mammary gland development: cell fate specification, stem cells and the microenvironment. *Development.* 2015; 142(6): 1028–1042.
- Kanakis GA, Nordkap L, Bang AK, Calogero AE, Bártfai G, Corona G, et al. EAA Clinical Practice Guidelines – Gynecomastia Evaluation and Management. *Andrology.* 2019; 7(6): 778–793.

- Kim J, Turan V, Oktay K. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. *J Clin Endocrinol Metab.* 2016; 101(4): 1364–1371.
- Lambertini M, Horicks F, Demeestere I. Use Chemotherapy-Induced of GnRH Analogs for Gonadotoxicity Prevention of. In: Donnez J, Kim SS. *Fertility Preservation: Principles and Practice.* 2nd ed. Cambridge: Cambridge University Press; 2021. 171 p.
- Mathew J, Perkins GH, Stephens T, Middleton LP, Yang W-T. Primary Breast Cancer in Men: Clinical, Imaging and Pathological Findings in 57 patients. *AJR Am J Roentgenol.* 2008; 191(6): 1631–1639.
- Montemurro P, Fischer S, Hager S, Hedén P. Secondary Breast Augmentation: Is There a Trend for Bigger Implants? *Aesthetic Plast Surg.* 2019 Feb; 43(1): 59–69.
- Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. *J Clin Oncol.* 2005; 23(19): 4347–4353.
- Pavlidis N, Pentheroudakis G. The pregnant mother with breast cancer: diagnostic and therapeutic management. *Cancer Treat Rev.* 2005; 31(6): 439–447.
- Pavlidis NA. Coexistence of pregnancy and malignancy. *Oncologist.* 2002; 7(4): 279–287.
- PDQ Adult Treatment Editorial Board. *PDQ Cancer Information Summaries: Male Breast Cancer Treatment (PDQ®)* [Internet]. Bethesda, MD: National Cancer Institut; 2021 [cit. 2021-03-01]. Dostupné z: <https://www.ncbi.nlm.nih.gov/books/NBK65792/>.
- Rodriguez AO, Chew H, Cress R, Xing G, McElvy S, Danielsen B, et al. Evidence of poorer survival in pregnancy-associated breast cancer. *Obstet Gynecol.* 2008; 112(1): 71–78.
- Stöblen F, Rezai M, Kümmel S. Imaging in patients with breast implants – results of the First International Breast (Implant) Conference 2009. *Insights Imaging.* 2010; 1(2): 93–97.
- Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Reproductive history and mortality after breast cancer diagnosis. *Obstet Gynecol.* 2004; 104(1): 146–154.
- Kapitola 15: Hrazená a nehrazená zdravotní péče, algoritmus vyšetřovacích metod v příkladech**
- Mamo.cz – *Program mamografického screeningu v České republice. Doporučení KOMD k vykazování výkonů a diagnóz ve screeningovém a diagnostickém vyšetřování prsů* (s platností od 1. 11. 2019) [Internet]. Brno: Masarykova univerzita; 2019 [cit. 2021-03-01]. Dostupné z: <https://www.mamo.cz/cs/lekari/indikace/vykazovani-vykonu-a-diagnoz/>.
- Mamo.cz – *Program mamografického screeningu v České republice. Screeningová vs. diagnostická mamografie* [Internet]. Brno: Masarykova univerzita; 2019 [cit. 2021-03-01]. Dostupné z: <https://www.mamo.cz/cs/lekari/screeningova-vs-diagnosticka-mamografie/>.
- Oborová zdravotní pojišťovna OZP. *Bezplatný preventivní program STOP rakovině prsu* [Internet]. Praha: OZP; 2020 [cit. 2021-03-01]. Dostupné z: <https://www.ozp.cz/benefity/zdravotne-preventivni-programy/stop-rakovine-prsu>.

Kapitola 16: Komunikace ve screeningu a diagnostice

Allgood PC, Maxwell AJ, Hudson S, Offman J, Hutchison G, Beattie C, et al. A randomised trial of the effect of postal reminders on attendance for breast screening. *Br J Cancer*. 2016; 114(2): 171–176.

European Commission Initiative on Breast Cancer (ECIBC). *Breast cancer guidelines and quality assurance* [Internet]. Ispra: JRC; 2021 [cit. 2021-03-12]. Dostupné z: <https://healthcare-quality.jrc.ec.europa.eu/>.

Haškovcová H, Pavlicová J. *Ošetřovatelství: ideály a realita v ambulantní péči*. Praha: Galén; 2013. 122 s.

Vidal C, Garcia M, Benito L, Milà N, Binefa G, Moreno V. Use of text-message reminders to improve participation in a population-based breast cancer screening program. *J Med Syst*. 2014; 38(9): 118.

aktivita proliferační 43

alergie na

– jod 114

– kontrastní paramagnetickou látku 132

– lokální anestetika 141

algoritmus vyšetřovacích metod 174

ALH 129

alkohol 62

amastie 81

anamnéza 71

– osobní 57

– rodinná 57

androgeny 163

anestezie lokální 140

anorexie 74

antigen karcinoembryonální 158

aplazie 81

aplikace MaSe 38

asistentky radiologické 24

aspekce 71

assessment 23

astma 146

asymetrie 145

atelie 81

augmentace 167

B

biomarkery 47

biopsie 39, 43, 135

– core 141

– – axily 140

– – pod sonografickou kontrolou 44

– – prsu 140

– core-cut 141

– navigovaná 136

– perkutánní 139

– prsu 139

– sentinelové uzliny 155

– tlustou jehlou 141

– ultrazvukem 141

– pod sonografickou kontrolou 44

– stereotakticky navigovaná 44

BRCA1 28, 57

BRCA2 28, 57

BRCA3 28, 57

BRCA4 28, 57

BRCA5 28, 57

BRCA6 28, 57

BRCA7 28, 57

BRCA8 28, 57

BRCA9 28, 57

BRCA10 28, 57

BRCA11 28, 57

BRCA12 28, 57

BRCA13 28, 57

BRCA14 28, 57

BRCA15 28, 57

BRCA16 28, 57

BRCA17 28, 57

BRCA18 28, 57

BRCA19 28, 57

BRCA20 28, 57

BRCA21 28, 57

BRCA22 28, 57

BRCA23 28, 57

BRCA24 28, 57

BRCA25 28, 57

BRCA26 28, 57

BRCA27 28, 57

BRCA28 28, 57

BRCA29 28, 57

BRCA30 28, 57

BRCA31 28, 57

BRCA32 28, 57

BRCA33 28, 57

BRCA34 28, 57

BRCA35 28, 57

BRCA36 28, 57

BRCA37 28, 57

BRCA38 28, 57

BRCA39 28, 57

BRCA40 28, 57

BRCA41 28, 57

BRCA42 28, 57

BRCA43 28, 57

BRCA44 28, 57

BRCA45 28, 57

BRCA46 28, 57

BRCA47 28, 57

BRCA48 28, 57

BRCA49 28, 57

BRCA50 28, 57

BRCA51 28, 57

BRCA52 28, 57

BRCA53 28, 57

BRCA54 28, 57

BRCA55 28, 57

BRCA56 28, 57

BRCA57 28, 57

BRCA58 28, 57

BRCA59 28, 57

BRCA60 28, 57

BRCA61 28, 57

BRCA62 28, 57

BRCA63 28, 57

BRCA64 28, 57

BRCA65 28, 57

BRCA66 28, 57

BRCA67 28, 57

BRCA68 28, 57

BRCA69 28, 57

BRCA70 28, 57

BRCA71 28, 57

BRCA72 28, 57

BRCA73 28, 57

BRCA74 28, 57

BRCA75 28, 57

BRCA76 28, 57

BRCA77 28, 57

BRCA78 28, 57

BRCA79 28, 57

BRCA80 28, 57

BRCA81 28, 57

BRCA82 28, 57

BRCA83 28, 57

BRCA84 28, 57

BRCA85 28, 57

BRCA86 28, 57

BRCA87 28, 57

BRCA88 28, 57

BRCA89 28, 57

BRCA90 28, 57

BRCA91 28, 57

BRCA92 28, 57

BRCA93 28, 57

BRCA94 28, 57

BRCA95 28, 57

BRCA96 28, 57

BRCA97 28, 57

BRCA98 28, 57

BRCA99 28, 57

BRCA100 28, 57

BRCA101 28, 57

BRCA102 28, 57

BRCA103 28, 57

BRCA104 28, 57

BRCA105 28, 57

BRCA106 28, 57

BRCA107 28, 57

BRCA108 28, 57

BRCA109 28, 57

BRCA110 28, 57

BRCA111 28, 57

BRCA112 28, 57

BRCA113 28, 57

BRCA114 28, 57

BRCA115 28, 57

BRCA116 28, 57

BRCA117 28, 57

BRCA118 28, 57

BRCA119 28, 57

BRCA120 28, 57

BRCA121 28, 57

BRCA122 28, 57

BRCA123 28, 57

BRCA124 28, 57

BRCA125 28, 57

BRCA126 28, 57

BRCA127 28, 57

BRCA128 28, 57

BRCA129 28, 57

BRCA130 28, 57

BRCA131 28, 57

BRCA132 28, 57

BRCA133 28, 57

BRCA134 28, 57

BRCA135 28, 57

BRCA136 28, 57

BRCA137 28, 57

BRCA138 28, 57

BRCA139 28, 57

BRCA140 28, 57

BRCA141 28, 57

BRCA142 28, 57

BRCA143 28, 57

BRCA144 28, 57

BRCA145 28, 57

BRCA146 28, 57

BRCA147 28, 57

BRCA148 28, 57

BRCA149 28, 57

BRCA150 28, 57

BRCA151 28, 57

BRCA152 28, 57

BRCA153 28, 57

BRCA154 28, 57

BRCA155 28, 57

BRCA156 28, 57

BRCA157 28, 57

BRCA158 28, 57

BRCA159 28, 57

BRCA160 28, 57

BRCA161 28, 57

BRCA162 28, 57

BRCA163 28, 57

BRCA164 28, 57

BRCA165 28, 57

BRCA166 28, 57

BRCA167 28, 57

BRCA168 28, 57

BRCA169 28, 57

BRCA170 28, 57

BRCA171 28, 57

BRCA172 28, 57

BRCA173 28, 57

BRCA174 28, 57

BRCA175 28, 57

BRCA176 28, 57

BRCA177 28, 57

BRCA178 28, 57

BRCA179 28, 57

BRCA180 28, 57

BRCA181 28, 57

BRCA182 28, 57

BRCA183 28, 57

BRCA184 28, 57

BRCA185 28, 57

BRCA186 28, 57

BRCA187 28, 57

BRCA188 28, 57

BRCA189 28, 57

BRCA190 28, 57

BRCA191 28, 57

BRCA192 28, 57

BRCA193 28, 57

BRCA194 28, 57

BRCA195 28, 57

BRCA196 28, 57

BRCA197 28, 57

BRCA198 28, 57

BRCA199 28, 57

BRCA200 28, 57

BRCA201 28, 57

BRCA202